U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
127998
Substance Class Protein
Created
by admin
on Sat Dec 17 17:30:33 UTC 2022
Edited
by admin
on Sat Dec 17 17:30:33 UTC 2022
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
8E4LAA4357
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 2D6
Common Name English
CYTOCHROME P450, FAMILY 2, SUBFAMILY D, POLYPEPTIDE 6
Common Name English
CYTOCHROME P 450 2D6
Common Name English
HUMAN CYTOCHROME P450 2D6
Common Name English
CYP2D6
Common Name English
Code System Code Type Description
CAS
330597-62-1
Created by admin on Sat Dec 17 17:30:49 UTC 2022 , Edited by admin on Sat Dec 17 17:30:49 UTC 2022
PRIMARY
FDA UNII
8E4LAA4357
Created by admin on Sat Dec 17 17:30:49 UTC 2022 , Edited by admin on Sat Dec 17 17:30:49 UTC 2022
PRIMARY
UNIPROT
P10635
Created by admin on Sat Dec 17 17:30:49 UTC 2022 , Edited by admin on Sat Dec 17 17:30:49 UTC 2022
PRIMARY
Related Record Type Details
Structure of VORTIOXETINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of OXYMETAZOLINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of PROADIFEN
INHIBITOR -> METABOLIC ENZYME
SELECTIVE
Structure of IXAZOMIB
SUBSTRATE -> METABOLIC ENZYME
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Structure of DRONEDARONE
INHIBITOR -> METABOLIC ENZYME
LOW
Ki
Structure of VERUBECESTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of RIPRETINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of DULOXETINE
INHIBITOR -> METABOLIC ENZYME
Structure of FLUVOXAMINE
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: Demethylatio
Structure of LOFEXIDINE
SUBSTRATE -> METABOLIC ENZYME
Lofexidine exposures were approximately 30% greater with co-administration of paroxetine a strong inhibitor of CYP2D6.
MAJOR
Structure of CIFENLINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PAROXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of DEFERASIROX
SUBSTRATE -> METABOLIC ENZYME
Structure of BUPIVACAINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TRIPELENNAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of IMIPRAMINE
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: 2-Hydroxylation
Structure of ENCORAFENIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of TAFENOQUINE
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of PALONOSETRON
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of FORMOTEROL
SUBSTRATE -> METABOLIC ENZYME
Structure of DPA-714 F-18
SUBSTRATE -> METABOLIC ENZYME
Structure of INDACATEROL
SUBSTRATE -> METABOLIC ENZYME
Structure of FLUVOXAMINE
INHIBITOR -> METABOLIC ENZYME
WEAK INHIBITOR
Structure of QUINIDINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of GLECAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of ASENAPINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of CICLESONIDE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of BEROTRALSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of BUPROPION
INHIBITOR -> METABOLIC ENZYME
Strong Inhibitors(2) 5-fold increase in AUC or > 80% decrease in CL
MAJOR
Structure of DRONEDARONE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of SKF-8742
INHIBITOR -> METABOLIC ENZYME
Structure of ARIPIPRAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of CIMETIDINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of ALVESPIMYCIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of FEBUXOSTAT
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of CYCLOHEXANAMINE, N-(3-ETHOXYPROPYL)-1-PHENYL-
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ENCORAFENIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TERBINAFINE
SUBSTRATE -> METABOLIC ENZYME
Structure of Valbenazine
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of CARVEDILOL, (-)-
SUBSTRATE -> METABOLIC ENZYME
Structure of ALDUMASTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of VILAZODONE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of DIPHENHYDRAMINE
SUBSTRATE -> METABOLIC ENZYME
N-demethylation of diphenhydramine is mainly catalyzed by CYP2D6 as a high-affinity P450 isozyme at a clinically relevant concentration.
MAJOR
Structure of COBICISTAT
INHIBITOR -> METABOLIC ENZYME
Structure of BETRIXABAN
SUBSTRATE -> METABOLIC ENZYME
Structure of DRONABINOL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ZOLPIDEM
SUBSTRATE -> METABOLIC ENZYME
Structure of CARBENDAZIM
INHIBITOR -> METABOLIC ENZYME
Structure of DACOMITINIB ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
IN-VITRO
Structure of ATOMOXETINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of MEPHEDRONE
SUBSTRATE -> METABOLIC ENZYME
In vitro studies suggest that mephedrone metabolic disposition is regulated by the highly polymorphic isoenzyme of CYP2D6 (Pedersen et al., 2013).
Structure of ALMOTRIPTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of MOTESANIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of RIVOGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of CJ-12458
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE SULFOXIDE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of BPR-1K871
SUBSTRATE -> METABOLIC ENZYME
Structure of LICOFELONE
SUBSTRATE -> METABOLIC ENZYME
Structure of CLOMIPRAMINE
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: 2- and 8-Hydroxylation
Structure of ABIRATERONE
INHIBITOR -> METABOLIC ENZYME
Abiraterone is an inhibitor of CYP2D6, in vivo. In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
Structure of SKF-26754A
INHIBITOR -> METABOLIC ENZYME
Structure of METOCLOPRAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of MIANSERIN
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: O-demethylation
Structure of OSILODROSTAT
INHIBITOR -> METABOLIC ENZYME
WEAK INHIBITION
Structure of HALOPERIDOL
SUBSTRATE -> METABOLIC ENZYME
Structure of MDE
MDE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of OTESECONAZOLE
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
IC50
Structure of belumosudil
SUBSTRATE -> METABOLIC ENZYME
Based on in vitro assessment, CYP3A4 (41.9%) was the predominant cytochrome P450 (CYP) isoform responsible for the metabolism of belumosudil although CYP2D6 (21.7%), CYP2C8 (14.2%), CYP1A2 (<5%), CYP2C19 (<5%), and UGT1A9 may also contribute to a lesser extent
Structure of VILOXAZINE
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
Structure of ESCITALOPRAM
SUBSTRATE -> METABOLIC ENZYME
Structure of ISTRADEFYLLINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TIOTROPIUM
SUBSTRATE -> METABOLIC ENZYME
Structure of PITAVASTATIN
SUBSTRATE -> METABOLIC ENZYME
Structure of PALIPERIDONE
SUBSTRATE -> METABOLIC ENZYME
Structure of FLIBANSERIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of OSILODROSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLORAMPHENICOL
WEAK INHIBITOR->METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
Structure of CEVIMELINE
SUBSTRATE -> METABOLIC ENZYME
Structure of Desloratadine
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLORPROMAZINE
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: N-demethylation Pharmacological action: Phenothiazine antipsychotic
SUBSTRATE
Unidentified
Structure of LOFEXIDINE
INHIBITOR -> METABOLIC ENZYME
Interaction with CYP2D6 substrates is not expected to be clinically significant.
MINOR
IC50
Structure of BUFURALOL
SUBSTRATE -> METABOLIC ENZYME
Structure of MECLIZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of DIPHENHYDRAMINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of NEBIVOLOL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TERFENADINE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of M-CHLOROPHENYLPIPERAZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PANOBINOSTAT
INHIBITOR -> METABOLIC ENZYME
Structure of BICIFADINE
SUBSTRATE -> METABOLIC ENZYME
Structure of TRAXOPRODIL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TEGILERIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ZIMLOVISERTIB
NON-INHIBITOR -> METABOLIC ENZYME
Structure of TAMSULOSIN
SUBSTRATE -> METABOLIC ENZYME
Structure of PITOLISANT
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of UPADACITINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of PERHEXILINE
SUBSTRATE -> METABOLIC ENZYME
Structure of OLICERIDINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ALECTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of MKC-963
SUBSTRATE -> METABOLIC ENZYME
Structure of 1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of TERFENADINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ANANDAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of TAFENOQUINE
SUBSTRATE -> METABOLIC ENZYME
Structure of RANOLAZINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of METHAMPHETAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ILOPERIDONE
SUBSTRATE -> METABOLIC ENZYME
Structure of TEGILERIDINE
INHIBITOR -> METABOLIC ENZYME
Structure of TEGASEROD
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of DONEPEZIL
SUBSTRATE -> METABOLIC ENZYME
Structure of TAMOXIFEN
SUBSTRATE -> METABOLIC ENZYME
Structure of METHADONE
SUBSTRATE -> METABOLIC ENZYME
Structure of TIMOLOL ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of AMITRIPTYLINE
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: N-demethylation
Structure of TOLTERODINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ELETRIPTAN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ALOGLIPTIN
SUBSTRATE -> METABOLIC ENZYME
Structure of CARVEDILOL
SUBSTRATE -> METABOLIC ENZYME
Structure of DELAVIRDINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of LUSUTROMBOPAG
INHIBITOR -> TARGET
Structure of ELAGOLIX
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of PACTIMIBE
SUBSTRATE -> METABOLIC ENZYME
Structure of DULOXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of DPA-714
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of NELONICLINE
SUBSTRATE -> METABOLIC ENZYME
2.1% conversion to M1
Structure of GALANTAMINE
SUBSTRATE -> METABOLIC ENZYME
O-demethylation, mediated by CYP2D6 was greater in extensive metabolizers of CYP2D6 than in poor metabolizers
MAJOR
Structure of VILAZODONE
INHIBITOR -> METABOLIC ENZYME
In vitro studies have shown that vilazodone is a moderate inhibitor of CYP2C19 and CYP2D6
Structure of TRICLABENDAZOLE SULFONE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of AZELASTINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ISAVUCONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of CITALOPRAM
SUBSTRATE -> METABOLIC ENZYME
IN VITRO
Structure of TASIMELTEON
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of PHA-543613
SUBSTRATE -> METABOLIC ENZYME
Structure of MAVOGLURANT
SUBSTRATE -> METABOLIC ENZYME
Structure of IMATINIB
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
Structure of ROLAPITANT
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
Structure of PIMAVANSERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of methyl-MA
SUBSTRATE -> METABOLIC ENZYME
Structure of CI-1007
SUBSTRATE -> METABOLIC ENZYME
Structure of IMRECOXIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of NALOXEGOL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TETRABENAZINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TICLOPIDINE
INHIBITOR -> METABOLIC ENZYME
Structure of SUNEPITRON
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of TROPISETRON
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-5212377
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of MIDOMAFETAMINE
SUBSTRATE -> METABOLIC ENZYME
IN-VIVO
Structure of RISPERIDONE
SUBSTRATE -> METABOLIC ENZYME
Structure of ONDANSETRON
SUBSTRATE -> METABOLIC ENZYME
Structure of FLUOXETINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of PAROXETINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of ETORICOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of KRO-105714
SUBSTRATE -> METABOLIC ENZYME
Structure of NICOTINE
SUBSTRATE -> METABOLIC ENZYME
Structure of BEROTRALSTAT
INHIBITOR -> METABOLIC ENZYME
MODERATE
Structure of ELIGLUSTAT
INHIBITOR -> METABOLIC ENZYME
Eliglustat also exhibited time-dependent inhibition (TDI) of CYP2D6.
Ki
Structure of OSU-6162
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MDMC
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ORANTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of TERIFLUNOMIDE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of TZB-30878
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of DEUTETRABENAZINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of SIMEPREVIR
INHIBITOR -> METABOLIC ENZYME
CYP2C8
IC50
Structure of TRAMADOL
SUBSTRATE -> METABOLIC ENZYME
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of .ALPHA.-PYRROLIDINOPENTIOPHENONE
SUBSTRATE -> METABOLIC ENZYME
Structure of EPINASTINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PANOBINOSTAT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of LORCASERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of SARPOGRELATE
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
IC50
Structure of (2-(4-METHOXY-3-PHENETHYLOXY-PHENYL)-ETHYL)-DIPROPYL-AMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of SELICICLIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CAPSAICIN
SUBSTRATE -> METABOLIC ENZYME
WEAK
Structure of ELIGLUSTAT
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of 4'-METHYL-.ALPHA.-PYRROLIDINOBUTIOPHENONE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of DESIPRAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of VELIPARIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of NAPHTHALENE
SUBSTRATE -> METABOLIC ENZYME
Structure of BORTEZOMIB
SUBSTRATE -> METABOLIC ENZYME
Structure of 5-METHOXY-N,N-DIISOPROPYLTRYPTAMINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of REVEFENACIN
SUBSTRATE -> METABOLIC ENZYME
Structure of DEXTROMETHORPHAN
SUBSTRATE -> METABOLIC ENZYME
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
Structure of OMEPRAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of RIFAMYCIN
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Structure of N-(3-METHOXYPROPYL)-1-PHENYLCYCLOHEXANAMINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ALVAMELINE
SUBSTRATE -> METABOLIC ENZYME
Structure of LAFADOFENSINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of EZLOPITANT
SUBSTRATE -> METABOLIC ENZYME
Structure of BRILAROXAZINE
SUBSTRATE -> METABOLIC ENZYME
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Structure of AMIODARONE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of DEBRISOQUIN
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLOROQUINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of DESFESOTERODINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of RIVOCERANIB
SUBSTRATE -> METABOLIC ENZYME
Structure of Desloratadine
INHIBITOR -> METABOLIC ENZYME
WEAK
Structure of TEMSIROLIMUS
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of APOMORPHINE
SUBSTRATE -> METABOLIC ENZYME
Structure of VECABRUTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of COBIMETINIB
INHIBITOR -> METABOLIC ENZYME
Cobimetinib is a reversible inhibitor of CYP3A4 and CYP2D6 in vitro.
REVERSIBLE
Structure of 2-AMINOTHIAZOLOBENZAZEPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PRALSETINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of NORQUETIAPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of LUMEFANTRINE
INHIBITOR -> METABOLIC ENZYME
In vitro, lumefantrine significantly inhibits the activity of CYP2D6 at therapeutic plasma concentrations
Structure of LETERMOVIR
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of REBOXETINE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of GABAPENTIN ENACARBIL
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of BMS-690514
SUBSTRATE -> METABOLIC ENZYME
Structure of UMECLIDINIUM
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MEQUITAZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of GDC-0425
SUBSTRATE -> METABOLIC ENZYME
Structure of CODEINE ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Structure of DELAVIRDINE
INDUCER -> METABOLIC ENZYME
Structure of METHOXYCHLOR
SUBSTRATE -> METABOLIC ENZYME
Structure of Mebufotenin
SUBSTRATE -> METABOLIC ENZYME
Structure of RITONAVIR
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of NORTRIPTYLINE
SUBSTRATE -> METABOLIC ENZYME
Pharmacological action: Tricyclic antidepressant drug (TCA)
Structure of TRAZODONE
SUBSTRATE -> METABOLIC ENZYME
Structure of TERBINAFINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of ETHYLMORPHINE
SUBSTRATE -> METABOLIC ENZYME
Structure of GOSOGLIPTIN
SUBSTRATE -> METABOLIC ENZYME
Structure of (+)-?-Dihydrotetrabenazine
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TELITHROMYCIN
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of CINACALCET
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of VILOXAZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of OLANZAPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ATOMOXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of CARVEDILOL, (+)-
SUBSTRATE -> METABOLIC ENZYME
Structure of RETAPAMULIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966